MKM Partners Upgrades Merck (MRK) to Buy

November 20, 2012 10:41 AM EST Send to a Friend
Get Alerts MRK Hot Sheet
Price: $59.96 +0.13%

Rating Summary:
    8 Buy, 11 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 9 | New: 42
Trade MRK Now!
Join SI Premium – FREE
MKM Partners upgraded Merck (NYSE: MRK) from Neutral to Buy with a price target of $51.00 (from $47.00).

The firm comments, "Between 2013 and 2017 we expect Merck to potentially launch 12 new products; the greatest number out of its U.S. peers. While the expected contribution from these potential launches is about average for the U.S. group, we think higher-than-average new product news flow could help Merck’s share performance over the next several years. Merck also has significantly below average patent exposure (14% of current sales) through 2017, even with the expected losses of Zetia and Vytorin in 2016. The net of these rankings implies that Merck is significantly undervalued on a forward looking basis and leads us to upgrade the company to a Buy rating."

The firm increased 2016 EPS estimate from $3.95 to $3.96 and rolling out a 2017 EPS estimate of $4.01.

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $43.34 yesterday.




You May Also Be Interested In


Related Categories

Analyst EPS Change, Analyst PT Change, Upgrades

Add Your Comment